Clinical Trials Browser

Phase 2/3 × OTHER × Endometrial Neoplasms × Clear all

Endometrial Neoplasms

NCT04159155 2025-08-12

CAN-STAMP

Phase 2/3 Terminated

11 enrolled

Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05316467 2025-08-11

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase 2/3 Recruiting

89 enrolled

GynecologicOther

Infertility, Obesity, Endometrial Neoplasms, Overweight

NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase 2/3 Recruiting

80 enrolled

Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase 2/3 Recruiting

29 enrolled

GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT05489848 2022-08-05

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Phase 2/3 Not yet recruiting

294 enrolled

Gynecologic

Endometrial Neoplasms

NCT03463252 2021-09-13

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Phase 2/3 Recruiting

224 enrolled

Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Clinical Trials

FEMUS

CAN-STAMP

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

RAINBO

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC